Stock Alert: Micron Technology Slides 5%; Q1 Earnings View Below Estimates

Shares of Micron Technology Inc. (MU) are losing more than 5 percent or $2.63 in Wednesday's morning trade at $48.08 after the company provided earnings outlook for the first quarter below analyst's estimates, even as its fourth-quarter earnings beat their expectations.

from RTT - Earnings https://ift.tt/30hd6ik
via IFTTT

Election Uncertainty May Weigh On Wall Street After Debate

The major U.S. index futures are pointing to a lower open on Wednesday, with stocks likely to extend the downward move seen in the previous session.

from RTT - Market Analysis https://ift.tt/2G39euD
via IFTTT

Dominion Energy Expects Transaction With Berkshire Hathaway Energy To Close Around November 1

Dominion Energy, Inc. (D) on Wednesday provided updates related to the pending sale of its gas transmission and storage assets to an affiliate of Berkshire Hathaway Inc. (BRK-A, BRK-B).

from RTT - Earnings https://ift.tt/3cHKyDA
via IFTTT

Pre-market Movers In Healthcare Sector: CTIC, SEEL, BNGO, ETON, ADIL.

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/2SixVFz
via IFTTT

This Week's Healthcare IPOs

The IPO activity in the U.S. pharma/biotech sector has had a strong showing so far this year, with 69 listings compared to only 46 during the same period last year. In the third quarter, 34 companies belonging to the healthcare sector were listed on the major stock exchanges in the US.

from RTT - Biotech https://ift.tt/36pufdL
via IFTTT

US casino operator Caesars agrees £2.9bn William Hill takeover

Deal is unanimously recommended by UK bookmaker’s directors

The US casino operator Caesars Entertainment has agreed a £2.9bn takeover of the British bookmaker William Hill.

The companies announced on Wednesday that Caesars would pay £2.72 per William Hill share in cash, a premium of more than a quarter compared with the price before the US company’s interest was first reported last week.

Continue reading...

from Mergers and acquisitions | The Guardian https://ift.tt/2SaNdfB

U.S. Stocks May Give Back Ground After Yesterday's Rally

The major U.S. index futures are currently pointing to a modestly lower open on Tuesday, with stocks likely to give back ground following the rally seen in the previous session.

from RTT - Market Analysis https://ift.tt/3kY5dGo
via IFTTT

AngioDynamics Guides FY21 Well Above Estimates - Quick Facts

While reporting financial results for the first quarter of fiscal 2021 on Tuesday, medical devices company AngioDynamics, Inc. (ANGO) provided adjusted earnings and net sales guidance for the full year 2021.

from RTT - Earnings https://ift.tt/30jpVbT
via IFTTT

Big Lots Guides Q3 EPS Well Above Estimates - Quick Facts

Discount retailer Big Lots, Inc. (BIG) provided on Tuesday the expected results for the third quarter of fiscal 2020. The company estimates comparable sales will increase in the mid-teens for the quarter.

from RTT - Earnings https://ift.tt/2HHp1j5
via IFTTT

McCormick Reinstates FY20 Outlook; Announces 2-for-1 Stock Split - Quick Facts

While reporting financial results for the third quarter on Tuesday, McCormick & Co., Inc. (MKC) reinstated its adjusted earnings and sales guidance for the full year 2020, reflecting strong business performance driven by expected sales growth.

from RTT - Earnings https://ift.tt/347pylY
via IFTTT

GNFT Soars On LabCorp Deal, INO's COVID-19 Vaccine Trial On Partial Hold, FDA Expands Xeljanz Label

Today's Daily Dose brings you news about Abeaona's leadership and Board transitions, GENFIT's deal with LabCorp., FDA hold on Inovio's planned Phase 2/3 Covid-19 vaccine trial, the new CEO of Merck KGaA, and label expansion of Pfizer's blockbuster drug Xeljanz.

from RTT - Biotech https://ift.tt/3idLj8s
via IFTTT

FDA Approves GlaxoSmithKline's Nucala To Treat Rare Blood Disorders

The U.S. Food and Drug Administration approved the first drug to treat adults and children aged 12 years and older with hypereosinophilic syndrome for six months or longer without another identifiable non-blood related cause of the disease. GlaxoSmithKline's Nucala (mepolizumab) is the first FDA-approved drug in nearly 14 years to treat this group of rare and debilitating blood diseases.

from RTT - Biotech https://ift.tt/3jeeedW
via IFTTT

Asda takeover: TDR-backed EG Group in pole position for £6.5bn deal

Billionaire owners of British petrol forecourts operator are Walmart’s preferred bidder

The billionaire owners of the British petrol forecourts operator EG Group have taken pole position in the £6.5bn race for control of Asda after being named the preferred bidder by the supermarket’s US owner.

Mohsin and Zuber Issa, who are working with the private-equity firm TDR Capital, have pushed out a rival offer from the private-equity firm Apollo Global Management.

Continue reading...

from Mergers and acquisitions | The Guardian https://ift.tt/2EIyeGM

Futures Pointing To Continued Strength On Wall Street

The major U.S. index futures are currently pointing to a higher opening on Monday, with stocks likely to extend the strong upward move seen in the previous session.

from RTT - Market Analysis https://ift.tt/3cEAR94
via IFTTT

Quotient Granted EUA From FDA For Its COVID-19 Antibody Test - Quick Facts

Diagnostics company Quotient Ltd. (QTNT) announced Monday that the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) on Friday for its COVID-19 antibody test. Before granting the EUA, the FDA reviewed not only its COVID-19 antibody test but also the MosaiQ Instrument and related software.

from RTT - Biotech https://ift.tt/3iixKVH
via IFTTT

FDA Puts INOVIO's IND For Phase 2/3 Trial Of COVID-19 Vaccine Candidate On Partial Clinical Hold

Biotechnology company INOVIO (INO) announced Monday that the U.S. Food and Drug Administration (FDA) has notified the company that it has additional questions about the company's planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA 2000 delivery device to be used in the trial.

from RTT - Biotech https://ift.tt/36cNVkJ
via IFTTT

Thor Industries Q3 Results Top Estimates - Quick Facts

Thor Industries, Inc. (THO) reported Monday net income for the second quarter of $119.2 million or $2.14 per share, up from $92.1 million or $1.67 per share in the prior-year quarter.

from RTT - Earnings https://ift.tt/2S6GlA0
via IFTTT

Pre-market Movers In Healthcare Sector: GNFT, HUGE, ACOR, AQST...

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/2S7ValT
via IFTTT

Caesars in advanced talks on £2.9bn William Hill takeover bid

US hotel and entertainment company makes offer for one of UK’s biggest bookmakers

The operator of the Las Vegas casino Caesars Palace has confirmed it is in “advanced discussions” about a possible £2.9bn takeover bid for the UK bookmaker William Hill.

Caesars Entertainment said it had offered 272p a share in cash after scrutinising the company’s books.

Continue reading...

from Mergers and acquisitions | The Guardian https://ift.tt/339si36

Week Ahead In Pharma: Clinical Trial Readouts, FDA Decision (ETON, SELB, CRBP.)

In the week ended September 25, Kaleido Biosciences Inc. (KLDO), which surged over 51%, was the biggest weekly gainer in the healthcare sector. Now, let's take a look at some of the stocks that are worth keeping an eye on in the week ahead.

from RTT - Biotech https://ift.tt/2S3OFk0
via IFTTT

Biotech Stocks Facing FDA Decision In October 2020

As of this writing, the FDA has approved 40 novel drugs so far this year compared to just 27 during the same period (Jan-Sep) last year. Now, let's take a look at the biotech stocks facing FDA decision in October.

from RTT - Biotech https://ift.tt/30avolk
via IFTTT

Caesars approaches UK's William Hill over potential takeover

One of the UK’s largest high street bookmakers at the centre of a possible US bidding war

William Hill, one of the UK’s largest and best-known high street bookmakers, is at the centre of a possible US bidding war that could mean it is bought by the operator of the Las Vegas casino, Caesars Palace.

Shares in the British gambling company surged by more than 40% on Friday after the bookie said it had received “separate cash proposals” from a private equity firm, Apollo Management International, which is currently in the running to buy Asda, and from the hotel and entertainment group, Caesars Entertainment.

Continue reading...

from Mergers and acquisitions | The Guardian https://ift.tt/2RWhPl5

Surge In Coronavirus Cases In Europe May Generate Selling Pressure

The major U.S. index futures are currently pointing to a lower open on Friday, with stocks likely to move back to the downside after ending the wild ride seen in the previous session modestly higher.

from RTT - Market Analysis https://ift.tt/3mOCrd3
via IFTTT

Pre-market Movers In Healthcare Sector: NVAX, JAGX, AYTU, ZLAB.

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/2FYGVxg
via IFTTT

Kloeckner Raises Q3, FY20 Adj. EBITDA Outlook - Quick Facts

Kloeckner & Co SE (KCO), a producer of steel and metal products, said Thursday that the negative impact of the COVID-19 pandemic on its operating business was further mitigated in the third quarter.

from RTT - Earnings https://ift.tt/3i7KRJf
via IFTTT

Worries About Economy, Elections May Weigh On Wall Street

The major U.S. index futures are pointing to a lower open on Thursday, with stocks likely to extend the sell-off seen over the course of the previous session.

from RTT - Market Analysis https://ift.tt/33UJbxB
via IFTTT

Jabil Guides Q1 In Line With Estimates - Quick Facts

While reporting preliminary, unaudited financial results for its fourth quarter and fiscal 2020 on Thursday, Jabil, Inc. (JBL) provided earnings and revenue guidance for the first quarter of fiscal 2021, in line with analysts' estimates.

from RTT - Earnings https://ift.tt/32XFLKV
via IFTTT

FactSet Guides FY21 Adj. EPS In Line With Estimates - Quick Facts

While reporting financial results for the fourth quarter and fiscal 2020 on Thursday, FactSet Research Systems, Inc. (FDS) initiated earnings and revenue outlook for the full-year 2021.

from RTT - Earnings https://ift.tt/3cpuGFQ
via IFTTT

Trader Joe's Southwest Style Sweet Potato Saute Bowl Recalled

GHSW, LLC. is recalling Trader Joe's Southwest Style Sweet Potato Sauté Bowl citing undeclared milk and egg allergens in the dressing, according to the Food and Drug Administration. The recall was initiated after it was discovered that the dressing in the bowl contains milk and egg, but are not declared on the label.

from RTT - Biotech https://ift.tt/361KCwD
via IFTTT

Darden Restaurants Guides Q2 EPS Above View; Reinstates Dividend - Quick Facts

While reporting financial results for the first quarter on Thursday, Darden Restaurants, Inc., (DRI) provided said it is providing financial outlook for the second quarter of fiscal 2021.

from RTT - Earnings https://ift.tt/3kMAts6
via IFTTT

Accenture Guides FY21 Below Estimates; Boosts Dividend 10% - Quick Facts

While reporting financial results for the fourth quarter and fiscal 2020 on Thursday, Accenture Plc (ACN) initiated earnings and revenue growth outlook for the full-year 2021.

from RTT - Earnings https://ift.tt/3hWZkYk
via IFTTT

Pre-market Movers In Healthcare Sector: BIOL, OTIC, ANPC, CEMI, LPCN, NAOV...

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/3kJuh3P
via IFTTT

IDEAYA Expands Clinical Trial Collaboration, Supply Agreement With Pfizer - Quick Facts

Precision medicine company IDEAYA Biosciences, Inc. (IDYA) announced Thursday that it has expanded its clinical trial collaboration and supply agreement with pharma major Pfizer Inc. (PFE) for an IDEAYA sponsored clinical combination study of IDE196, a Protein Kinase C (PKC) inhibitor, and crizotinib, a cMET inhibitor to which Pfizer has exclusive worldwide rights.

from RTT - Biotech https://ift.tt/3mLvZUd
via IFTTT

JNJ Begins Phase 3 COVID-19 Vaccine Trial, Another Headstone In Alzheimer's Graveyard, PFE On Watch

Today's Daily Dose brings you news about AC Immune's disappointing results in Alzheimer's trial, Actinium Pharma's progress in the Acute Myeloid Leukemia study, Johnson & Johnson initiating phase III trial of its COVID-19 vaccine candidate, and Pfizer's regulatory catalyst.

from RTT - Biotech https://ift.tt/3crTY6j
via IFTTT

HELLA Q1 Adj. EBIT Declines, Adj. Sales Down 10.6%; Confirms Outlook - Quick Facts

HELLA (HLKHF) reported a first quarter EBIT of minus 115 million euros due to provisions for restructuring measures in Germany. Adjusted EBIT declined to 56 million euros from 111 million euros, last year. Adjusted EBIT margin was 4.2 percent compared to 7.3 percent.

from RTT - Earnings https://ift.tt/2RUHlHe
via IFTTT

Traders May Continue To Pick Up Stocks At Reduced Levels

The major U.S. index futures are pointing to a higher open on Wednesday, with stocks likely to extend the upward move seen over the course of the previous session.

from RTT - Market Analysis https://ift.tt/3mJYAcD
via IFTTT

General Mills Q1 Profit Tops Estimates, Organic Net Sales Up 10%; Raises Dividend

General Mills (GIS) reported first quarter adjusted earnings per share of $1.00, up 27 percent in constant currency, primarily driven by higher adjusted operating profit and higher after-tax earnings from joint ventures, partially offset by a higher adjusted effective tax rate and higher average shares outstanding. On average, 17 analysts polled by Thomson Reuters expected the company to report profit per share of $0.87, for the quarter. Analysts' estimates typically exclude special items. Operating profit was $854 million, up 29 percent year-on-year. Constant-currency adjusted operating profit increased 22 percent, for the quarter.

from RTT - Earnings https://ift.tt/32VIZ1S
via IFTTT

Sun Pharma Recalls One Lot Of Diabetes Drug RIOMET ER Oral Suspension - Quick Facts

Sun Pharmaceutical Industries, Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd., on Wednesday recalled one lot of type 2 diabetes medication RIOMET ER (metformin hydrochloride for extended-release oral suspension), 500 mg per 5 mL.

from RTT - Biotech https://ift.tt/3cpuRkl
via IFTTT

Pfizer Says FDA Accepts SNDA For XALKORI, Grants Priority Review - Quick Facts

Pharma major Pfizer Inc. (PFE) announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to its supplemental New Drug Application(sNDA)for XALKORI (crizotinib) for the treatment of pediatric patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive.

from RTT - Biotech https://ift.tt/2RPo4H5
via IFTTT

JinkoSolar Q2 Profit Surges - Quick Facts

Solar module manufacturer JinkoSolar Holding Co., Ltd. (JKS) reported Wednesday that net income attributable to the company's ordinary shareholders was RMB318.0 million or $45.0 million in the second quarter, sharply higher than RMB125.4 million in the year-ago quarter. Earnings per American depositary share (ADS) were RMB6.55 or $0.93, compared to RMB1.26 last year.

from RTT - Earnings https://ift.tt/2RTIWx7
via IFTTT

JNJ Initiates Pivotal Global Phase 3 Clinical Trial Of Janssen's COVID-19 Vaccine Candidate

Johnson & Johnson (JNJ) announced Wednesday the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies.

from RTT - Biotech https://ift.tt/3iX3DUO
via IFTTT

Pre-market Movers In Healthcare Sector: POAI, ACET, GNCA, WVE, NAOV.

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/33SWpe3
via IFTTT

Healthcare IPOs For Sep 25

The end of the third quarter is fast approaching. The third quarter IPO activity in the U.S. pharma/biotech sector has had a strong showing, with 30 listings so far for the period.

from RTT - Biotech https://ift.tt/300Je9Q
via IFTTT

Private equity group Apollo leads £6.5bn race to buy Asda

Two bidders in running to snap up Walmart-owned chain as Lone Star drops out

Private equity firm Apollo Global Management is thought to have edged into the lead in the £6.5bn bidding war for Asda after rival Lone Star Funds dropped out.

It is thought a third bid from private equity firm TDR Capital remains in the running – the group is understood to have been working on a deal with the billionaire Issa brothers, who are behind the British forecourts operator EG Group.

Continue reading...

from Mergers and acquisitions | The Guardian https://ift.tt/3hUsmri

U.S. Stocks May Show A Lack Of Direction In Early Trading

The major U.S. index futures are currently pointing to a roughly flat open on Tuesday, with stocks likely to show a lack of direction in early trading.

from RTT - Market Analysis https://ift.tt/363FfgJ
via IFTTT

Pre-market Movers In Healthcare Sector: ANPC, SAVA, FLGT, RMTI, ONTX.

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/2ROmpBH
via IFTTT

GoodRx Holdings To Debut On Nasdaq Tomorrow

Santa Monica-based GoodRx Holdings, which operates a digital platform for consumer healthcare products and services, is scheduled to make its debut on the Nasdaq Global Select Market under the symbol "GDRX" on September 23, 2020.

from RTT - Biotech https://ift.tt/3iTlqfz
via IFTTT

ABIO Joins Battle Against COVID-19, ERYP On Watch, LPCN To Report NASH Study Results In Q1

Today's Daily Dose brings you news about ARCA biopharma's progress related to its COVID-19 drug candidate, ADC Therapeutics' submission of Loncastuximab tesirine BLA, BridgeBio's initiation of ADH1 study, ERYTECH Pharma's anticipated milestones, and the progress in Lipocine's NASH trial.

from RTT - Biotech https://ift.tt/2EqFw1M
via IFTTT

Futures Pointing To Lower Open On Wall Street

The major U.S. index futures are currently pointing to a sharply lower opening on Monday, with stocks likely to extend the downward move seen over the past few sessions.

from RTT - Market Analysis https://ift.tt/2RK0n3d
via IFTTT

Pre-market Movers In Healthcare Sector: ONTX, ACST, VXRT, CMPS, LPCN...

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/2FSqVfZ
via IFTTT

Taysha Gene Therapies To Debut On Nasdaq On Sept 24

Dallas, Texas-based Taysha Gene Therapies is scheduled to make its debut on the Nasdaq Global Select Market under the symbol "TSHA" on September 24, 2020. Taysha Gene Therapies is a patient-centric gene therapy company developing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system.

from RTT - Biotech https://ift.tt/33LFLNl
via IFTTT

Week Ahead In Pharma: Data Readouts, FDA Decision (AQST, BCRX, ETON...)

Let's take a look at some of the healthcare stocks that merit attention in the coming week.

from RTT - Biotech https://ift.tt/32MkW5m
via IFTTT

MPs to debate Arm Holdings $40bn sale despite Nvidia boss's guarantees

Jensen Huang’s offer of legally binding guarantees to safeguard UK interests fail to allay doubts

MPs are to debate the controversial $40bn (£31bn) sale of the UK’s biggest tech company, Arm Holdings, after assurances from its US buyer failed to quell lingering concern that the deal will harm British interests.

Jensen Huang, the founder and chief executive of California-based tech firm Nvidia, moved to allay fears about the transaction on Friday, publicly declaring himself willing to offer legally binding guarantees on jobs and investment.

Continue reading...

from Mergers and acquisitions | The Guardian https://ift.tt/3iI7Lbb

United States Steel Projects Improved Adjusted Results In Q3 - Quick Facts

United States Steel Corp. (X) announced the company expects its third quarter adjusted loss per share to be approximately $1.45. On average, nine analysts polled by Thomson Reuters expect the company to report a loss per share of $1.53, for the quarter. Analysts' estimates typically exclude special items.

from RTT - Earnings https://ift.tt/2ZOWrCK
via IFTTT

Acella Pharma Recalls Thyroid Drugs For Sub Potency

Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020.

from RTT - Biotech https://ift.tt/3hKuMc5
via IFTTT

Traders May Take A Breather Following Recent Roller Coaster Ride

The major U.S. index futures are currently pointing to a roughly flat open on Friday, suggesting stocks may show a lack of direction on the day.

from RTT - Market Analysis https://ift.tt/3hKxkHb
via IFTTT

Seattle Genetics, Astellas Say Phase 3 Trial Of PADCEV Meets Primary Endpoint - Quick Facts

Biotechnology company Seattle Genetics, Inc. (SGEN) and Japanese pharmaceutical company Astellas Pharma Inc. (ALPMY, ALPMY) announced Friday that a phase 3 trial of PADCEV (enfortumab vedotin-ejfv) met its primary endpoint of overall survival compared to chemotherapy.

from RTT - Biotech https://ift.tt/33E4JhQ
via IFTTT

Pre-market Movers In Healthcare Sector: IMMP, SAVA, SNOA, CRDF, INO.

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/32DL5TM
via IFTTT

CCXI To Face FDA In April, CRDF Soars On Colorectal Cancer Trial Data, VCNX In Deal With MRK

Today's Daily Dose brings you news about ChemoCentryx's regulatory catalyst in July, Checkpoint's $20 million bought deal offering, CytRx's potential milestone payment, Cardiff Oncology's encouraging colorectal cancer trial results, and Vaccinex's near-term catalyst.

from RTT - Biotech https://ift.tt/33BTaHX
via IFTTT

Stock Alert: Herman Miller Jumps 19% After Profit Surges

Shares of Herman Miller, Inc. (MLHR) are climbing more than 19 percent or $4.97 in Thursday's morning trade at $30.85 after the office furniture maker reported a jump in profit for the first quarter from last year and reinstated its quarterly cash dividend.

from RTT - Earnings https://ift.tt/3c9zZci
via IFTTT

Renewed Concerns About Economic Outlook May Weigh On Wall Street

The major U.S. index futures are pointing to a sharply open on Thursday, with stocks likely to extend the pullback seen late in the previous session.

from RTT - Market Analysis https://ift.tt/3hFv0RF
via IFTTT

Pre-market Movers In Healthcare Sector: SRNE, GNCA, VXRT, BNTX, INO...

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/3kr2hlv
via IFTTT

Revisiting Mersana Therapeutics (MRSN)

Shares of Mersana Therapeutics Inc. (MRSN), which closed at an all-time high of $25.70 yesterday, have gained an impressive 340 percent year-to-date, thanks to positive developments related to its clinical programs.

from RTT - Biotech https://ift.tt/3kubRUP
via IFTTT

China could provide stumbling block in Arm sale to Nvidia

Article in Chinese state-backed Global Times calls for intervention in deal

China is emerging as a potential stumbling block to the controversial $40bn (£31bn) sale of the UK’s largest tech firm, Arm Holdings, as the British government wavers on whether to intervene in the deal.

Labour, unions and Arm’s co-founder have urged ministers either to block the sale of the chip designer by Japanese investment firm SoftBank to US firm Nvidia, or insist upon legally-binding conditions to ensure British interests are not harmed.

Continue reading...

from Mergers and acquisitions | The Guardian https://ift.tt/2H70bZI

This Week's Healthcare IPOs

In the healthcare sector, two companies made their stock market debut in the first half of this month.

from RTT - Biotech https://ift.tt/2ZI0fW1
via IFTTT

Expectations Of Dovish Fed May Generate Early Buying Interest

The major U.S. index futures are pointing to a higher open on Wednesday, with stocks likely to extend the rebound seen over the two previous sessions.

from RTT - Market Analysis https://ift.tt/2H81Myr
via IFTTT

Pre-market Movers In Healthcare Sector: TLSA, APDN, AVEO, TNXP, ETON.

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/2FHysOB
via IFTTT

ARPO To Report Glaucoma Trial Data In Q4, ARDX To Face FDA In April, PFE's Pipeline Update

Today's Daily Dose brings you news about Aerpio Pharma's clinical trial catalyst, Adicet Bio's reverse merger with resTORbio, FDA decision date of Ardelyx's Tenapanor, Cel-Sci's phase III study of Multikine for the treatment of newly diagnosed head and neck cancer, and an update on Pfizer's pipeline.

from RTT - Biotech https://ift.tt/3c3LtOo
via IFTTT

Cambridge staff 'fobbed off' at meeting over Arm sale to Nvidia, says union

UK government urged to intervene in SoftBank’s $40bn deal with US tech firm

Opposition to the $40bn (£31bn) sale of the UK’s largest tech firm, Arm Holdings, is mounting, as the trade union Unite said staff concerned about their future had been “fobbed off” and the company’s local MP urged the government to act.

The US software company Nvidia said on Monday it had agreed to buy Arm, a global leader in designing chips for smartphones, computers and tablets, from the Japanese tech investment business SoftBank.

Related: Arm's sale to Nvidia makes sense but we need binding guarantees | Nils Pratley

Continue reading...

from Mergers and acquisitions | The Guardian https://ift.tt/2FHRd49

Eli Lilly, Boehringer Ingelheim: FDA Grants Fast Track Designation To Jardiance

Boehringer Ingelheim and Eli Lilly and Co. (LLY) said Tuesday that the U.S. Food and Drug Administration or FDA has granted Fast Track designation for the development of Jardiance (empagliflozin) to prevent hospitalization for heart failure and reduce the risk of mortality following an acute myocardial infarction in patients with and without diabetes.

from RTT - Biotech https://ift.tt/33uuMrE
via IFTTT

Tech Stocks May Continue To Lead The Way Higher On Wall Street

The major U.S. index futures are currently pointing to a higher open on Tuesday, with stocks poised to extend the rally seen in the previous session.

from RTT - Market Analysis https://ift.tt/3iBqjcQ
via IFTTT

Metacrine To Debut On Nasdaq Tomorrow

San Diego, California-based Metacrine is scheduled to go public on the Nasdaq Global Select Market under the symbol "MTCR" on September 16, 2020.

from RTT - Biotech https://ift.tt/2E0sszM
via IFTTT

Pre-market Movers In Healthcare Sector: NVUS, MRNS, ABIO, LPCN, CLRB, VXRT.

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/35Bk05p
via IFTTT

MRNS Catches Eye, SAVA Soars On Alzheimer's Study, ETNB Abuzz Over NASH Trial, GILD Snaps Up IMMU

Today's Daily Dose brings you news about Gilead's acquisition of Immunomedics, Marinus' CDKL5 deficiency disorder trial results, Seattle Genetics' oncology collaborations with Merck, 89bio's NASH trial data, and Cassava Sciences' Alzheimer's trial results.

from RTT - Biotech https://ift.tt/3mk0SPj
via IFTTT

Vaxart Says FDA Clears IND Application For Oral COVID-19 Vaccine - Quick Facts

Biotechnology company Vaxart, Inc. (VXRT) announced Monday that the U.S. Food and Drug Administration (FDA) has completed its review of the Company's Investigational New Drug (IND) application for its Phase 1 clinical trial evaluating its oral COVID-19 vaccine candidate. The company also provided an update on its COVID-19 program.

from RTT - Biotech https://ift.tt/33uDrdo
via IFTTT

U.S. Stocks May Open Higher On Tech Strength, Coronavirus Vaccine News

The major U.S. index futures are currently pointing to a higher opening on Monday following the mixed performance seen last Friday.

from RTT - Market Analysis https://ift.tt/3bXfLCo
via IFTTT

Lilly, Incyte Announce Initial Data From Adaptive COVID-19 Treatment Trial - Quick Facts

Eli Lilly and Co. (LLY) and Incyte Corp. (INCY) announced Monday initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

from RTT - Biotech https://ift.tt/2DWK9jI
via IFTTT

Pre-market Movers In Healthcare Sector: IMMU, SAVA, DVAX, ENLV, VXRT...

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/3mkQSp6
via IFTTT

AstraZeneca Covid Vaccine Trial Resumption In US Not Yet Known; UK Trial Resumed

British drug major AstraZeneca, which had halted the trial of coronavirus vaccine AZD1222 last week, has resumed the trial in the U.K, while it is still not certain when the company will start its US trial again. The company said it will continue to work with other global health authorities and be guided as to when other clinical trials can resume.

from RTT - Biotech https://ift.tt/32rZIte
via IFTTT

Markets lifted by deal-making frenzy - business live

A flurry of M&A activity sees Nvidia buy ARM for $40bn, Gilead acquire Immunomedics for $21bn and TikTok team up with Oracle to avoid (it hopes) a US ban

• Introduction: Three important deals
• TikTok: ByteDance ‘to partner with Oracle’ in US
• Job cut fears as Nvidia buys ARM
• ARM founder: It’s a disaster

8.16am BST

European stock markets have also begun the week brightly, with gains across the board.

In London, the FTSE 100 index has jumped by 42 points or 0.7% to 6037 points, its highest level in nearly three weeks.

M&A appears to be the main focus as we start a new week with US pharma company Gilead Sciences buying cancer drug maker Immunomedics for $21bn, while Softbank appears to have finally agreed a price with US graphics chip maker NVidia, for UK chip company ARM Holdings of $40bn, as it seeks to bolster its balance sheet after a rather troubled 2019, as well as the recent scrutiny of its big derivative bets on some big US tech shares.

Softbank shares have moved sharply higher in Asia trading this morning on news of the sale, however this optimism needs to be tempered.

8.08am BST

Stock markets across the Asia-Pacific region rallied today, with Softbank leading the way.

Shares in Softbank jumped by 9%, as traders applauded the sale of Arm to Nvidia.

8.04am BST

ARM founder Hermann Hauser adds that Boris Johnson’s government should block Nvidia’s acquisition:

“This is a UK company, it’s clearly in the national interest that it stays a UK company, so the government clearly has the power to prevent that [the deal]”

7.59am BST

Hermann Hauser, ARM’s co-founder, says the sale of ARM to a US firm was an “absolute disaster for Cambridge, the UK and Europe”.

He warned that it would lead to job losses in the UK, destroy the UK firm’s business model and impinge on UK economic sovereignty. Any promises made on jobs are “meaningless unless they are legally enforceable,” pointing to the takeover of Cadbury by US company Kraft in 2010.

“The headquarters [will] move to the United States as they inevitably will when ARM becomes a division of Nvidia. This will lead to job losses in Cambridge, Manchester, Belfast, Warwick where ARM employs thousands of people.

Secondly, Nvidia will destroy ARM’s business model… which is being the Switzerland of the semiconductor industry of dealing with over 500 licensees, most of which are competitors of Nvidia.

“Which means that if hundreds of UK companies that incorporate ARM in their products want to export it to anywhere in the world including to China which is a major market, this decision on whether they are allowed to export it will be made in the White House, and not in Downing Street.”

https://t.co/3husABs2lg ARM, crown jewel of UK tech, sold on by Softbank to Nvidia for $40billion. Deal described by cofounder Hermann Hauser as a disaster - he's writing to 10 Downing Street warning it will destroy the firm's business model and make Britain "a US vassal state."

7.36am BST

Good morning, and welcome to our rolling coverage of the world economy, the financial markets, the eurozone and business.

The City has woken up to an dealmaking frenzy this morning, with three tie-ups with serious ramifications well beyond the markets being announced.

The Washington Post reported that Oracle had been chosen by ByteDance as a ‘“technology partner” to allay US concerns, and Reuters quoted a source as saying it would be a restructuring rather than a sale, with Oracle handling TikTok’s US user data. The source did not disclose how much of TikTok’s US operations ByteDance and its investors would continue to own.

ByteDance will need approval for the deal from both Washington and Beijing. It is not clear whether Trump, who wants a US technology company to own most of TikTok in the United States, will approve the proposal.

Related: TikTok: ByteDance 'to partner with Oracle' in US after rejecting Microsoft bid

https://t.co/3husABs2lg ARM, crown jewel of UK tech, sold on by Softbank to Nvidia for $40billion. Deal described by cofounder Hermann Hauser as a disaster - he's writing to 10 Downing Street warning it will destroy the firm's business model and make Britain "a US vassal state."

“Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat.

We will now continue to explore its potential to treat many other types of cancer, both as a monotherapy and in combination with other treatments.

Gentle recovery as trials resume.

European Opening Calls:#FTSE 6059 +0.45%#DAX 13278 +0.57%#CAC 5068 +0.68%#AEX 554 +0.42%#MIB 19938 +0.59%#IBEX 6986 +0.62%#OMX 1805 +0.18%#STOXX 3335 +0.58%#IGOpeningCall

Continue reading...

from Mergers and acquisitions | The Guardian https://ift.tt/33pHSqb

Checkpoint (CKPT) Hits Yearly High, Will The Rally Sustain?

Shares of Checkpoint Therapeutics Inc. (CKPT), which recently touched a 52-week high of $3.83, have gained more than 90 percent so far this year and trade around $3.

from RTT - Biotech https://ift.tt/33nQDkx
via IFTTT

Week Ahead In Pharma: FDA Decisions, Data Readouts, ESMO Presentations

The week that passed by saw shares of Nano-X Imaging Ltd. (NNOX) make the biggest weekly advance, gaining over 66%. The Israeli "digital X-ray device" maker made its debut on the Nasdaq as recently as August 21. Now, let's take a look at some of the stocks that merit attention in the coming week.

from RTT - Biotech https://ift.tt/33hTafO
via IFTTT

This Day That Year: 10x Genomics Inc. (TXG)

Shares of 10x Genomics Inc. (TXG), which closed at an all-time high of $125 on Friday, have gained 64 percent so far this year. It was on this day last year, i.e. on September 12, 2019, that the company made its debut on the Nasdaq Global Select Market by setting a public offering at $39 per share.

from RTT - Biotech https://ift.tt/35pyAgq
via IFTTT

Tech Stocks May Lead Another Early Rebound On Wall Street

The major U.S. index futures are currently pointing to a higher open on Friday following the sharp pullback seen over the course of the previous session.

from RTT - Market Analysis https://ift.tt/3m8NTjs
via IFTTT

Pre-market Movers In Healthcare Sector: GENE, GLPG, NVAX, QTNT, EVFM.

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/32ipQGL
via IFTTT

AVXL On Watch, STSA Reels With Pain As Migraine Study Fails, HSTO To Report Alopecia Data In Q4

Today's Daily Dose brings you news about the anticipated clinical trial catalysts of Anavex Life, Histogen, and Lyra Therapeutics; disappointing migraine trial results of Satsuma, and the upcoming regulatory catalyst of Sol-Gel.

from RTT - Biotech https://ift.tt/3hlsKiu
via IFTTT

Stock Alert: Virtusa Shares Up 24% In Early Trade

Shares of Virtusa Corp. (VRTU) are rising over 24% in pre-market today, after the company announced a merger deal, under which funds affiliated with Baring Private Equity Asia would acquire all outstanding common shares of Virtusa for $51.35 per share in an all-cash transaction valued at about $2.0 billion. The deal is anticipated to close in the first half of 2021.

from RTT - Before the Bell https://ift.tt/3m8Uz0X
via IFTTT

Stock Alert: SelectQuote Climbs 16% After Upbeat Q4 Results

Shares of SelectQuote Inc. (SLQT) are rising more than 16 percent or $3.29 in Thursday's morning trade at $23.34 after the insurance company's quarterly results beat analysts' expectations.

from RTT - Earnings https://ift.tt/2DRVFwY
via IFTTT

Stock Alert: RH Jumps To New 52-week High After Q2 Results Beat View

Shares of RH (RH) are surging almost 25 percent or $80.22 in Thursday's morning trade at $401.30, after touching a new 52-week high of $405.55 as the luxury furniture retailer's second-quarter earnings results beat analysts' estimates.

from RTT - Earnings https://ift.tt/3ij7v1U
via IFTTT

Corvus Pharma Updates On Clinical Trial Of CPI-006 For Patients With COVID-19 - Quick Facts

Biopharmaceutical company Corvus Pharmaceuticals, Inc. (CRVS) announced Thursday updated data from its ongoing Phase 1 study investigating the potential for CPI-006 to provide a novel immunotherapy approach for patients with COVID-19.

from RTT - Biotech https://ift.tt/35q3NAe
via IFTTT

Futures Pointing To Mixed Open On Wall Street

The major U.S. index futures are pointing to a mixed open on Thursday, as the Dow futures have moved to the downside but the Nasdaq futures are notably higher.

from RTT - Market Analysis https://ift.tt/2ZslsDw
via IFTTT

Pre-market Movers In Healthcare Sector: SNOA, AMYT, IBIO, CVAC, PRPO.

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/2ReGCQO
via IFTTT

AMPE Says Ampion Improves COVID-19 Symptoms, AMYT At Ease, ITCI Impresses With Depression Trial Data

Today's Daily Dose brings you news about Ampio Pharma's phase I results of Ampion treatment in COVID-19 patients, Amryt Pharma's Epidermolysis Bullosa trial results, FDA's expanded approval for Trelegy Ellipta, Intra-Cellular Therapies' promising results from bipolar depression trial, Takeda's disappointing data from TOURMALINE-MM2 trial.

from RTT - Biotech https://ift.tt/3bKtI6Q
via IFTTT

After Hours Market: Sonoma Pharmaceuticals, RH, SelectQuote Gain; GameStop, Quotient Slip

Sonoma Pharmaceuticals, Inc. (SNOA) - Shares of the drug company jumped 20% in extended trading session Wednesday after the company announced launch of two new products in Australia. Sonoma and Te Arai BioFarma announced the launch of two new products available in Australia. Both of these new products are based on Sonoma's patented Microcyn and Microdacyn technology and are available without prescription through pharmacies.

from RTT - Earnings https://ift.tt/2DJaWzV
via IFTTT

Stock Alert: Intra-Cellular Therapies Shares Surge 82% In Early Trade

Shares of Intra-Cellular Therapies Inc. (ITCI) are rising over 82% in pre-market today, after the company reported positive topline results from its Phase 3 clinical trial (Study 402) evaluating lumateperone as adjunctive therapy to lithium or valproate in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.

from RTT - Before the Bell https://ift.tt/3bHgeJ1
via IFTTT

American Eagle Outfitters Reports Better Than Expected Q2 Results - Quick Facts

American Eagle Outfitters, Inc. (AEO) reported a second quarter adjusted loss per share of $0.03 compared to profit of $0.39, last year. The company noted that its adjusted results for the quarter excluded $0.05 of COVID-19 related expenses and restructuring costs. On average, 16 analysts polled by Thomson Reuters expected the company to report a loss per share of $0.16, for the quarter. Analysts' estimates typically exclude special items.

from RTT - Earnings https://ift.tt/3jYS8w6
via IFTTT

Pfizer, BioNTech Say MRNA-based Vaccine Candidate Protected Rhesus Macaques In Preclinical Studies

Pfizer Inc. (PFE) and BioNTech SE (BNTX) on Wednesday announced preliminary preclinical data in mouse and non-human primate models from their BNT162b2 mRNA-based vaccine program against SARS-CoV-2, the virus that causes COVID-19, or the coronavirus disease.

from RTT - Biotech https://ift.tt/33dt6m1
via IFTTT

U.S. Stocks May Regain Ground In Early Trading

The major U.S. index futures are pointing to a higher open on Wednesday, with stocks likely to regain ground after moving sharply lower over the three previous sessions.

from RTT - Market Analysis https://ift.tt/2RbmsHE
via IFTTT

Lovesac Q2 Loss Narrows; Net Sales Up 28.7% - Quick Facts

Lovesac Co. (LOVE), a direct-to-consumer specialty furniture brand, on Wednesday reported net loss for the second quarter that narrowed to $1.11 million or $0.08 per share, from $4.77 million or $0.33 per share in the previous-year quarter.

from RTT - Earnings https://ift.tt/2R9qGzj
via IFTTT

Pre-market Movers In Healthcare Sector: TRIL, AERI, NVAX, VXRT, MRNA.

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/2F3r28p
via IFTTT

AZN Pauses COVID-19 Vaccine Trial, ALBO Hits New High, CRBP Plunges, PFE To Invest In TRIL

Today's Daily Dose brings you news about AstraZeneca pausing its phase 3 study of COVID-19 vaccine candidate, Albireo's positive data from phase 3 trial of Odevixibat in progressive familial intrahepatic cholestasis, Corbus' disappointing results from its phase 3 trial of Lenabasum in diffuse cutaneous systemic sclerosis, and RedHill's promising 'in vitro' data of COVID-19 drug candidate.

from RTT - Biotech https://ift.tt/35ilrWk
via IFTTT

Merck: Gefapixant Significantly Reduced Cough Frequency Compared To Placebo In Two Phase 3 Trials

Merck & Co. Inc. (MRK) on Tuesday announced the results from two pivotal Phase 3 trials, COUGH-1 and COUGH-2, evaluating the efficacy and safety of gefapixant (MK-7264) for the potential treatment of refractory or unexplained chronic cough.

from RTT - Biotech https://ift.tt/337S6eC
via IFTTT

Pre-market Movers In Healthcare Sector: ALBO, BIOC, KMDA, BNTX.

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/3bF5R8c
via IFTTT

Week Ahead In Pharma: Data Readouts, Results From Interim Analysis, ERS Congress Presentation

The week that passed by saw shares of Aimmune Therapeutics (AIMT) make the biggest weekly advance, gaining over 170%, as the peanut allergy drug maker is all set to be acquired by Nestle Health Science for $34.50 per share in cash. Now, let's take a look at some of the pharma stocks that merit attention in the coming week.

from RTT - Biotech https://ift.tt/2ET0jeH
via IFTTT

Pfizer Covid-19 Vaccine Update Likely In October

Pfizer CEO Albert Bourla said an update could be provided on the late-stage trial of their vaccine candidate for coronavirus (COVID-19) as early as October 2020. "We are in a very advanced stage" and have already enrolled 23,000 out of the required 30,000 volunteer patients for the 'big pivotal' Phase 3 trial that began in late July," he said.

from RTT - Biotech https://ift.tt/3lT7IuO
via IFTTT

Futures Pointing To Mixed Open On Wall Street

The major U.S. index futures are currently pointing to a mixed open on Friday following the broad-based sell-off seen in the previous session. The Dow futures are currently up by 102 points but the Nasdaq futures down by 155 points.

from RTT - Market Analysis https://ift.tt/3jJFSPZ
via IFTTT

Laurentian Bank Financial Q3 Profit Declines, But Results Beat View

Laurentian Bank Financial Group (LB.TO) on Friday reported third-quarter net income of C$36.2 million or C$0.77 per share, down from C$47.8 million or C$1.05 per share in the year-ago period.

from RTT - Earnings https://ift.tt/3h7heHv
via IFTTT

Pre-market Movers In Healthcare Sector: SONN, OBSV, OSUR, CVAC, OCGN...

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/3jPZfHf
via IFTTT

Stock Alert: Duluth Hits New 52-week High After Earnings Surprise

Shares of Duluth Holdings Inc. (DLTH) are rising almost 6 percent or $0.61 in Thursday's morning trade at $11.08, after touching a new 52-week high of $11.57 as the company reported better-than-expected quarterly results.

from RTT - Earnings https://ift.tt/3lLxBN7
via IFTTT

Profit Taking May Lead To Initial Weakness On Wall Street

The major U.S. index futures are pointing to a lower open on Thursday, with stocks likely to give back ground following the rally seen in the previous session.

from RTT - Market Analysis https://ift.tt/32SnRIz
via IFTTT

Synalloy Not Issuing FY20 Outlook - Quick Facts

While reporting its financial results for the second quarter on Thursday, Synalloy Corp. (SYN) said that due to the uncertainty related to the COVID-19 pandemic, it has suspended all fiscal 2020 guidance and is not providing guidance at this time.

from RTT - Earnings https://ift.tt/2EXa0se
via IFTTT

Campbell Soup Guides Q1 In Line With Estimates - Quick Facts

While reporting financial results for the fourth quarter on Thursday, Campbell Soup Co. (CPB) provided adjusted earnings and sales guidance for the first quarter of fiscal 2021, given the uncertain operating environment due to the COVID-19 pandemic.

from RTT - Earnings https://ift.tt/3bkCsAg
via IFTTT

Pre-market Movers In Healthcare Sector: SNSS, NNVC, STRO, FLGT, LPCN...

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/31Tnj5E
via IFTTT

AGTC Abuzz, AMRN Slumps & CORT Soars As Oral Arguments Commence, FLGT Gears Up, NNVC On Watch

Today's Daily Dose brings you news about Applied Genetic's upcoming presentation, oral arguments in patent suits of Amarin and Corcept, Fulgent's partnership with New York City Health and Hospitals, NanoViricides' update on COVID-19 drug development, and Sunesis Pharma's reverse stock split, among others.

from RTT - Biotech https://ift.tt/3jHoYBq
via IFTTT

Mylan Recalls Certain Lots Of Amiodarone HCl, Tranexamic Acid Injections

Generic and specialty pharma company Mylan N.V. said its U.S.-based business Mylan Institutional LLC recalled four lots of Amiodarone HCl Injection, USP and Tranexamic Acid Injection, USP for potential interchanging of cartons, according to the U.S. Food and Drug Administration or FDA.

from RTT - Biotech https://ift.tt/2QR1FbS
via IFTTT

Stock Alert: GSX Techedu Tumbles 11% On SEC Probe

Shares of GSX Techedu Inc. (GSX) are falling more than 11 percent or $10.70 in Wednesday's morning trade at $83.99 after the China-based online tutoring service provider disclosed an investigation by the U.S. Securities and Exchange Commission.

from RTT - Earnings https://ift.tt/354mxES
via IFTTT

U.S. Stocks Poised To Extend Recent Upward Trend

The major U.S. index futures are pointing to a higher open on Wednesday, with stocks poised to extend their recent upward trend.

from RTT - Market Analysis https://ift.tt/2YWiLJY
via IFTTT

Guess? Approves Resumption Of Cash Dividend Program - Quick Facts

While reporting its financial results for the first quarter on Wednesday, Guess? Inc. (GES) said it is not providing detailed guidance for the third quarter ending October 31, 2020 or the full fiscal year ending January 30, 2021, due to the uncertain impact of the COVID-19 on its operations.

from RTT - Earnings https://ift.tt/3512bfR
via IFTTT

Macy's Q2 Results Stronger Than Anticipated; Shares Rise

Macy's, Inc. (M) reported a second quarter adjusted loss per share of $0.81 compared to profit of $0.28, previous year. On average, 14 analysts polled by Thomson Reuters expected the company to report a loss per share of $1.77, for the quarter. Analysts' estimates typically exclude special items.

from RTT - Earnings https://ift.tt/2QOVXYm
via IFTTT

Lands' End Initiates Q3, Q4 Net Revenue Growth Guidance - Quick Facts

While reporting its financial results for the second quarter on Wednesday, uni-channel retailer Lands' End, Inc. (LE) provided revenue growth guidance for the third and the fourth quarter of fiscal 2020, based on the stabilization and improved visibility in the business.

from RTT - Earnings https://ift.tt/2EXMV8J
via IFTTT

Pre-market Movers In Healthcare Sector: DFFN, CVAC, ADTX, ADMA, PSTV...

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/3bjZJlH
via IFTTT

TreeHouse Foods Recalls Signature Select Granola Bars

TreeHouse Foods, Inc. has recalled certain Chewy Granola Bars sold under the brand name Signature Select, citing misbranding and the presence of undeclared peanut, a known allergen. The recall involves 18 Count / 15.2 oz package of Signature Select Chewy Granola Bars - Chocolate Chip with UPC Number 2113028363 and best if used by date of January 21, 2021.

from RTT - Biotech https://ift.tt/2ENwXOE
via IFTTT

ATNX To Face FDA In Feb, ICPT Trims Workforce, JNCE Jumps On GILD Deal, SNY's Kevzara Flops Again

Today's Daily Dose brings you news about regulatory catalysts of Athenex and Vertex Pharma, layoffs in Intercept, licensing deal between Jounce and Gilead, and Sanofi's repurposed arthritis drug failing to meet goals in the COVID-19 trial.

from RTT - Biotech https://ift.tt/3gQMpqe
via IFTTT

Stock Alert: Zoom Hits New 52-week High After Quarterly Results

Shares of Zoom Video Communications Inc. (ZM) are surging almost 37 percent or $119.71 in Tuesday's morning trade at $444.81, after earlier touching a new 52-week high of $447.88 on better-than-expected quarterly results and increased outlook for the full year.

from RTT - Earnings https://ift.tt/34UlffB
via IFTTT

Stock Alert: J.Jill Shares Surge Over 113% In Early Trade

Shares of J.Jill Inc. (JILL) are soaring over 113% in pre-market today, after the company announced a Transaction Support Agreement with lenders holding greater than 70.0% of the company's term loans to strengthen its balance sheet and position the company for long-term growth.

from RTT - Before the Bell https://ift.tt/31KBJoG
via IFTTT

Nasdaq Likely To See Further Upside Amid Strength Among Tech Stocks

The major U.S. index futures are currently pointing to a mixed open on Tuesday after the major averages ended the previous session on opposite sides of the unchanged line.

from RTT - Market Analysis https://ift.tt/3bi3uIv
via IFTTT

Pre-market Movers In Healthcare Sector: APM, TTOO, BCRX, ZSAN, BNTX...

What's moving these stocks in the pre-market hours today?

from RTT - Biotech https://ift.tt/3be63vf
via IFTTT